Bain Capital Life Sciences Investors, LLC Arcutis Biotherapeutics, Inc. Transaction History
Bain Capital Life Sciences Investors, LLC
- $489 Million
- Q2 2024
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 1,030,703 shares of ARQT stock, worth $9.65 Million. This represents 1.96% of its overall portfolio holdings.
Number of Shares
1,030,703
Previous 2,011,687
48.76%
Holding current value
$9.65 Million
Previous $19.9 Million
51.92%
% of portfolio
1.96%
Previous 3.01%
Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
193Shares Held
127MCall Options Held
5.43MPut Options Held
257K-
Jennison Associates LLC11.6MShares$108 Million0.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY10MShares$93.6 Million3.89% of portfolio
-
Rubric Capital Management LP New York, NY9.82MShares$91.9 Million2.7% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$82.2 Million4.82% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$80.7 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $563M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...